Genmab AS
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.7% | -87.1% | +29.2% | +611.2% | +16.3% | -98.4% | +778.8% | +10.5% | +3.2% | -14.7% | +28.4% | – | |
| – | +59.5% | -78.6% | +3.7% | +875.0% | +23.4% | -98.2% | +821.9% | +1.8% | +39.2% | -19.2% | +28.8% | – | |
| – | -1.7% | -87.3% | +30.4% | +601.3% | +15.9% | -98.4% | +776.1% | +11.1% | +1.0% | -14.4% | +28.4% | – | |
| – | -6.7% | -82.8% | +7.8% | +532.4% | +16.7% | -98.0% | +588.8% | -1.9% | +46.9% | -15.8% | +3.9% | – | |
| – | +11.3% | -8.2% | +4.3% | -3.2% | +44.4% | -89.9% | +14.3% | +2.8% | +40.5% | -20.2% | +23.5% | – | |
| – | -2.2% | -84.0% | +12.0% | +514.6% | +24.6% | -98.2% | +611.5% | -0.6% | +44.9% | -16.9% | +9.2% | – | |
| – | -0.9% | -93.1% | +103.4% | +790.7% | +2.8% | -98.7% | +1,200.8% | +27.5% | -47.2% | -6.8% | +80.2% | – | |
| – | -25.0% | -33.3% | +375.0% | -5.3% | +200.0% | -98.6% | +1,122.7% | -66.7% | +1,362.2% | +156.3% | -2.1% | – | |
| – | -65.3% | -73.1% | +23.3% | +459.9% | +109.5% | -99.0% | +1,077.6% | +14.0% | -88.6% | +35.5% | +297.2% | – | |
| – | -49.5% | -80.1% | +82.5% | +335.6% | -153.6% | – | +1,106.1% | -6.9% | -70.5% | -11.9% | -138.0% | – | |
| – | -69.6% | -70.0% | +5.7% | +523.6% | +203.7% | -99.3% | +1,070.5% | +19.4% | -92.3% | +72.1% | +469.6% | – | |
| – | -64.1% | -73.2% | +21.8% | +580.2% | +6.9% | -98.3% | +1,048.4% | +12.3% | -80.4% | +89.1% | +130.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.